SomatoKine. Insmed.
SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potential injectable insulin sensitizer for the management of type 1 and type 2 diabetes in patients who are less sensitive to insulin therapy. By July 2002, the FDA had granted SomatoKine Orphan Drug status for the treatment of GHIS. Also at this time, a phase II trial in children suffering from GHIS was initiated. In September 2002, Insmed expected to initiate a further clinical trial in GHIS in early 2003, and planned to continue phase II development in type 1 and type 2 diabetes.
Norman
Peter
P
Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. peter.norman2@btinternet.com
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011993:Recombinant Fusion Proteins / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D007004:Hypoglycemic Agents; D011993:Recombinant Fusion Proteins; C475619:somatoKine